David Muccino

976 citations

28 papers · 481 indexed · 1 hit paper · h-index 11

Pulmonary and Respiratory Medicine top 5%
Physiology top 10%
Emergency Medical Services top 5%
Gastroenterology top 5%
Physiology top 10%

Co-authors: Surinder S. Birring Allison Martin Nguyen Carmen La Rosa Jonathan Schelfhout John A. Smith Lorcan McGarvey Alyn H. Morice Peter V. Dicpinigaitis
Topics: Respiratory and Cough-Related Research (25 papers)Voice and Speech Disorders (15 papers)Asthma and respiratory diseases (11 papers)
Cited by: Emergency Medical Services Gastroenterology Physiology
Journals: The Lancet Journal of Allergy and Clinical Immunology Value in Health
Partner nations: United States United Kingdom Japan

In The Last Decade

David Muccino

26 papers receiving 472 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

2022 178 citations Lorcan McGarvey, Surinder S. Birring et al. The Lancet profile →

Peers

Countries citing papers authored by David Muccino

Since Specialization

Citations

This map shows the geographic impact of David Muccino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Muccino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Muccino more than expected).

Fields of papers citing papers by David Muccino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Muccino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Muccino. The network helps show where David Muccino may publish in the future.

Co-authorship network of co-authors of David Muccino

This figure shows the co-authorship network connecting the top 25 collaborators of David Muccino. A scholar is included among the top collaborators of David Muccino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Muccino. David Muccino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Safety and Efficacy of Depemokimab in Patients with Type 2 Asthma: A Single-Arm, Open-Label Extension Study (AGILE) 2026 ·Journal of Allergy and Clinical Immunology ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),David Muccino,(unknown),(unknown),(unknown),(unknown)	0
2	Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough 2022 ·Lung ·Jonathan Schelfhout,Allison Martin Nguyen,Surinder S. Birring,Elizabeth D. Bacci,Margaret Vernon,David Muccino,Carmen La Rosa,John A. Smith	12
3	A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough 2022 ·Allergology International ·Akio Niimi,Hironori Sagara,Masashi Kikuchi,(unknown),Asako Sato,(unknown),Carmen La Rosa,David Muccino	10
4	Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough 2022 ·Annals of Allergy Asthma & Immunology ·Peter V. Dicpinigaitis,Surinder S. Birring,Michael S. Blaiss,Lorcan McGarvey,Alyn H. Morice,Ian Pavord,Imran Satia,John A. Smith,Carmen La Rosa,Qing Li,Allison Martin Nguyen,Jonathan Schelfhout,Anjela Tzontcheva,David Muccino	16
5	Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsbreakdown → 2022 ·The Lancet ·Lorcan McGarvey,Surinder S. Birring,Alyn H. Morice,Peter V. Dicpinigaitis,Ian Pavord,Jonathan Schelfhout,Allison Martin Nguyen,Qing Li,Anjela Tzontcheva,(unknown),Stuart A. Green,Carmen La Rosa,David Muccino,John A. Smith	178
6	Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough 2022 ·Therapeutic Advances in Respiratory Disease ·Allison Martin Nguyen,Jonathan Schelfhout,David Muccino,Elizabeth D. Bacci,Carmen La Rosa,Margaret Vernon,Surinder S. Birring	36
7	Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups 2022 ·Lung ·John A. Smith,Surinder S. Birring,Peter V. Dicpinigaitis,Lorcan McGarvey,Alyn H. Morice,Ian Pavord,Imran Satia,Stuart Green,(unknown),Carmen La Rosa,Qing Li,Allison Martin Nguyen,Jonathan Schelfhout,David Muccino	6
8	Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant 2021 ·Lung ·Alyn H. Morice,Surinder S. Birring,John A. Smith,Lorcan McGarvey,Jonathan Schelfhout,Allison Martin Nguyen,Zhi Jin Xu,Wen‐Chi Wu,David Muccino,Mandel Sher	28
9	Validation of a visual analog scale for assessing cough severity in patients with chronic cough 2021 ·Therapeutic Advances in Respiratory Disease ·Allison Martin Nguyen,Elizabeth D. Bacci,Margaret Vernon,Surinder S. Birring,Carmen La Rosa,David Muccino,Jonathan Schelfhout	65
10	Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant 2021 ·Peter V. Dicpinigaitis,Surinder S. Birring,Alyn H. Morice,John A. Smith,Ian Pavord,Lorcan McGarvey,Anjela Tzontcheva,Qing Li,Allison Martin Nguyen,Jonathan Schelfhout,David Muccino,Carmen La Rosa	1
11	Baseline Cough Severity and Quality of Life in Patients with Chronic Cough Participating in Two Global Phase 3 Randomized Controlled Clinical Trials 2021 ·Surinder S. Birring,Peter V. Dicpinigaitis,Lorcan McGarvey,Alyn H. Morice,Ian Pavord,John A. Smith,(unknown),Q. Li,Allison Martin Nguyen,Jonathan Schelfhout,Anjela Tzontcheva,Zhi Jin Xu,David Muccino,Carmen La Rosa	1
12	Comorbid Conditions and Medical History Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Clinical Trials (COUGH-1 and COUGH-2) 2021 ·Journal of Allergy and Clinical Immunology ·Peter V. Dicpinigaitis,Surinder S. Birring,Lorcan McGarvey,Alyn H. Morice,Ian Pavord,John A. Smith,Carmen La Rosa,Qing Li,Allison Martin Nguyen,Jonathan Schelfhout,Anjela Tzontcheva,David Muccino	1
13	Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough 2020 ·ERJ Open Research ·David Muccino,Alyn H. Morice,Surinder S. Birring,Peter V. Dicpinigaitis,Ian Pavord,Christopher Assaid,Huub Jan Kleijn,Azher Hussain,Carmen La Rosa,Lorcan McGarvey,John A. Smith	42
14	Defining Minimal Clinically Important Differences (MCID) in Chronic Cough: Analyses of Objective Cough Counts from a Phase 2 Randomized Controlled Trial 2019 ·Journal of Allergy and Clinical Immunology ·Allison Martin Nguyen,David Muccino,Surinder S. Birring,Elizabeth D. Bacci,Margaret Vernon,Daniel Mines,John A. Smith	6
15	Defining Minimal Clinically Important Differences (MCID) on the Leicester Cough Questionnaire (LCQ): Analyses of a Phase 2 Randomized Controlled Trial in Chronic Cough 2019 ·Journal of Allergy and Clinical Immunology ·Surinder S. Birring,David Muccino,Elizabeth D. Bacci,Margaret Vernon,Allison Martin Nguyen	15
16	Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough 2019 ·Pulmonary Pharmacology & Therapeutics ·David Muccino,Stuart Green	31
17	Evaluation of Cough Triggers Among Responders and Non-Responders of Treatment with MK-7264, a P2X3 Receptor Antagonist 2019 ·Journal of Allergy and Clinical Immunology ·Mandel Sher,Surinder S. Birring,John A. Smith,Lorcan McGarvey,Alyn H. Morice,Wen‐Chi Wu,Jin Xu,David Muccino	1
18	Rationale and Design of Two, Phase 3, Randomized Controlled Trials (COUGH-1 and COUGH-2) of Gefapixant, A P2x3 Receptor Antagonist, in Refractory and Unexplained Chronic Cough 2019 ·David Muccino,AH Morice,Surinder S. Birring,Lorcan McGarvey,Peter V. Dicpinigaitis,Ian Pavord,Andrew M. Tershakovec,Michael M. Kitt,Yunfei Zheng,C. Assaid,John A. Smith	1
19	Estimation Of Pulmonary Arterial Hypertension On Productivity Losses In The United States 2014 ·Value in Health ·Vijay N. Joish,C. Kreilick,Rebecca Germino,David Muccino	1
20	The Burden of Illness of Pulmonary Arterial Hypertension: A Managed Care Perspective in the United States 2013 ·Value in Health ·Vijay N. Joish,David Muccino,C. Kreilick,(unknown),(unknown),Stephen C. Mathai	1

About David Muccino

David Muccino is a scholar working on Emergency Medical Services, Physiology and Pulmonary and Respiratory Medicine, having authored 28 papers that have together received 481 indexed citations. Recurring topics across this work include Respiratory and Cough-Related Research (25 papers), Voice and Speech Disorders (15 papers) and Asthma and respiratory diseases (11 papers). The work is most often cited by research in Emergency Medical Services (122 citations), Gastroenterology (88 citations) and Physiology (352 citations). David Muccino has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Surinder S. Birring, Allison Martin Nguyen, Carmen La Rosa, Jonathan Schelfhout, John A. Smith, Lorcan McGarvey, Alyn H. Morice, Peter V. Dicpinigaitis, Ian Pavord and Margaret Vernon. Their work appears in journals such as The Lancet, Journal of Allergy and Clinical Immunology and Value in Health.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact